AR082804A1 - Formas cristalinas de un inhibidor del factor xa - Google Patents
Formas cristalinas de un inhibidor del factor xaInfo
- Publication number
- AR082804A1 AR082804A1 ARP110103159A ARP110103159A AR082804A1 AR 082804 A1 AR082804 A1 AR 082804A1 AR P110103159 A ARP110103159 A AR P110103159A AR P110103159 A ARP110103159 A AR P110103159A AR 082804 A1 AR082804 A1 AR 082804A1
- Authority
- AR
- Argentina
- Prior art keywords
- degrees
- crystalline form
- crystal forms
- factor inhibitor
- betrixaban maleate
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- DTSJEZCXVWQKCL-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-(5-chloropyridin-2-yl)-2-[[4-(n,n-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide Chemical class OC(=O)\C=C/C(O)=O.C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 DTSJEZCXVWQKCL-BTJKTKAUSA-N 0.000 abstract 3
- 229950011103 betrixaban Drugs 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37933910P | 2010-09-01 | 2010-09-01 | |
| US201161454396P | 2011-03-18 | 2011-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082804A1 true AR082804A1 (es) | 2013-01-09 |
Family
ID=45773260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103159A AR082804A1 (es) | 2010-09-01 | 2011-08-30 | Formas cristalinas de un inhibidor del factor xa |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8946269B2 (https=) |
| EP (1) | EP2611779B1 (https=) |
| JP (4) | JP2013536864A (https=) |
| CN (1) | CN103261161B (https=) |
| AR (1) | AR082804A1 (https=) |
| AU (1) | AU2011295909B2 (https=) |
| CA (1) | CA2810004C (https=) |
| ES (1) | ES2603084T3 (https=) |
| IL (1) | IL224698A (https=) |
| NZ (1) | NZ608442A (https=) |
| PT (1) | PT2611779T (https=) |
| TW (1) | TW201221128A (https=) |
| WO (1) | WO2012031017A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980876B2 (en) | 2010-10-28 | 2015-03-17 | The Procter & Gamble Company | Inhibition of microbial growth by aconitase inhibition |
| US20150224091A1 (en) * | 2011-08-31 | 2015-08-13 | Portola Pharmaceuticals, Inc. | Prevention and treatment of thrombosis in medically ill patients |
| TWI616987B (zh) * | 2012-03-16 | 2018-03-01 | 樂仕特拉公司 | 光子材料中介層的方法及系統 |
| US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| CN104693114B (zh) * | 2013-12-10 | 2019-08-16 | 四川海思科制药有限公司 | 一种贝曲西班的改进的制备方法 |
| CN105085387A (zh) * | 2014-05-20 | 2015-11-25 | 四川海思科制药有限公司 | 贝曲西班盐及其制备方法和用途 |
| WO2017091757A1 (en) | 2015-11-24 | 2017-06-01 | Portola Pharmaceuticals, Inc. | Isotopically enriched betrixaban |
| CN106995405A (zh) * | 2016-01-25 | 2017-08-01 | 重庆医药工业研究院有限责任公司 | 一种贝曲西班马来酸盐无定型物及其制备方法 |
| US20190300483A1 (en) * | 2016-06-02 | 2019-10-03 | Dr. Reddy's Laboratories Limited | POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT |
| EP3254674A1 (en) | 2016-06-08 | 2017-12-13 | Sandoz Ag | Pharmaceutical compositions of betrixaban maleate |
| EP3293174A1 (en) | 2016-09-09 | 2018-03-14 | Sandoz Ag | Crystalline salts of betrixaban |
| WO2018069936A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof |
| CN107382897B (zh) * | 2017-07-10 | 2021-05-04 | 浙江宏元药业股份有限公司 | 一种贝曲西班的中间体及其制备方法和应用 |
| EP3510996A1 (en) * | 2018-01-11 | 2019-07-17 | Sandoz AG | Pharmaceutical compositions of betrixaban |
| CN108570003A (zh) * | 2018-06-01 | 2018-09-25 | 浙江宏元药业股份有限公司 | 一种贝曲西班马来酸盐的一水无定形及其制备方法 |
| CN113905715B (zh) | 2019-06-28 | 2025-04-15 | 宝洁公司 | 光增强处理方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9226238D0 (en) | 1992-12-16 | 1993-02-10 | Scherer Ltd R P | Encapsulation apparatus and process |
| US6140351A (en) | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| DE10322469A1 (de) | 2003-05-19 | 2004-12-16 | Bayer Healthcare Ag | Heterocyclische Verbindungen |
| KR101195801B1 (ko) | 2004-06-18 | 2012-11-05 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제 |
| US7696352B2 (en) | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| PE20070717A1 (es) * | 2005-11-08 | 2007-08-17 | Millennium Pharm Inc | Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida |
| NZ572418A (en) | 2006-05-05 | 2011-08-26 | Millennium Pharm Inc | Factor xa inhibitors |
| US20080051578A1 (en) | 2006-08-24 | 2008-02-28 | Georg Dahmann | Substituted biaryls, process for their manufacture and use thereof as medicaments |
| CN101595092B (zh) | 2006-11-02 | 2012-02-01 | 米伦纽姆医药公司 | 合成因子xa抑制剂的医药盐的方法 |
| KR101472765B1 (ko) | 2006-12-08 | 2014-12-15 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법 |
| WO2008086226A2 (en) | 2007-01-05 | 2008-07-17 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| EA020531B1 (ru) | 2007-04-13 | 2014-11-28 | Милленниум Фармасьютикалз, Инк. | КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИКОАГУЛИРУЮЩЕГО СРЕДСТВА С СОЕДИНЕНИЕМ, КОТОРОЕ ДЕЙСТВУЕТ КАК ИНГИБИТОР ФАКТОРА Ха |
| KR101509829B1 (ko) | 2007-05-02 | 2015-04-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법 |
| EP2915564B1 (en) | 2007-09-28 | 2020-11-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor XA inhibitors and methods of using the same |
| MX2011004907A (es) * | 2008-11-14 | 2011-07-29 | Portola Pharm Inc | Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre. |
| AR079491A1 (es) | 2009-12-17 | 2012-02-01 | Millennium Pharm Inc | Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura. |
| AR082803A1 (es) | 2010-09-01 | 2013-01-09 | Portola Pharm Inc | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p |
-
2011
- 2011-08-30 AR ARP110103159A patent/AR082804A1/es unknown
- 2011-08-30 TW TW100131157A patent/TW201221128A/zh unknown
- 2011-08-31 CA CA2810004A patent/CA2810004C/en not_active Expired - Fee Related
- 2011-08-31 PT PT117574673T patent/PT2611779T/pt unknown
- 2011-08-31 US US13/223,023 patent/US8946269B2/en active Active
- 2011-08-31 EP EP11757467.3A patent/EP2611779B1/en not_active Not-in-force
- 2011-08-31 WO PCT/US2011/050057 patent/WO2012031017A1/en not_active Ceased
- 2011-08-31 NZ NZ60844211A patent/NZ608442A/en not_active IP Right Cessation
- 2011-08-31 CN CN201180052042.4A patent/CN103261161B/zh not_active Expired - Fee Related
- 2011-08-31 JP JP2013527286A patent/JP2013536864A/ja active Pending
- 2011-08-31 AU AU2011295909A patent/AU2011295909B2/en not_active Ceased
- 2011-08-31 ES ES11757467.3T patent/ES2603084T3/es active Active
-
2013
- 2013-02-13 IL IL224698A patent/IL224698A/en active IP Right Grant
-
2015
- 2015-09-24 JP JP2015187427A patent/JP2015232046A/ja active Pending
-
2017
- 2017-11-16 JP JP2017221050A patent/JP2018024709A/ja active Pending
-
2019
- 2019-04-23 JP JP2019081907A patent/JP2019135258A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN103261161B (zh) | 2016-04-27 |
| WO2012031017A1 (en) | 2012-03-08 |
| EP2611779B1 (en) | 2016-08-10 |
| AU2011295909A1 (en) | 2013-04-04 |
| US20120071519A1 (en) | 2012-03-22 |
| JP2013536864A (ja) | 2013-09-26 |
| EP2611779A1 (en) | 2013-07-10 |
| PT2611779T (pt) | 2016-11-21 |
| NZ608442A (en) | 2015-04-24 |
| CA2810004C (en) | 2019-09-10 |
| US8946269B2 (en) | 2015-02-03 |
| JP2015232046A (ja) | 2015-12-24 |
| ES2603084T3 (es) | 2017-02-23 |
| JP2019135258A (ja) | 2019-08-15 |
| TW201221128A (en) | 2012-06-01 |
| CN103261161A (zh) | 2013-08-21 |
| IL224698A (en) | 2017-01-31 |
| AU2011295909B2 (en) | 2015-05-21 |
| CA2810004A1 (en) | 2012-03-08 |
| JP2018024709A (ja) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082804A1 (es) | Formas cristalinas de un inhibidor del factor xa | |
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| AR073298A1 (es) | Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv. | |
| SMT201400126B (it) | Uso di amisulpride per il trattamento di nausea e vomito post-operatori | |
| GT201400033A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| UY40179A (es) | Sal hemi-tolueno de (3s,5s,6r,8s)-8-alil-6-(3-clorofenil)-5-(4- clorofenil)-3-isopropil-8-metil-2,3,5,6,7,8-hexahidrooxazolo [3,2-a]piridin-4-io naftaleno-1-sulfonato, y su preparación | |
| MY185130A (en) | Romidepsin solid forms and uses thereof | |
| CR20110457A (es) | Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma | |
| SMT201400055B (it) | Composti di tioacetato, composizioni e metodi d'uso | |
| AR090151A1 (es) | Compuestos inhibidores de raf | |
| BR112015022782A2 (pt) | composto, composição farmacêutica, combinação, e, uso de um composto | |
| BR112013000650A2 (pt) | poliptídeos de fator ix e métodos de uso dos mesmos. | |
| UY33541A (es) | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas | |
| SMT201400008B (it) | Uso di betanecolo per il trattamento di xerostomia | |
| PE20140698A1 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2, 4-diamina | |
| NI200800294A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen. | |
| EP2761583A4 (en) | SECURE E-MAIL CONVERSIONS | |
| MX2016007522A (es) | Estimuladores de guanilato ciclasa soluble (sgc). | |
| PL2635119T3 (pl) | Zastosowanie kompozycji zawierającej parietynę jako stymulatora wzrostu | |
| IL224450B (en) | Crystalline forms of pyrimido[6,1-a] isoquinolin-4-one compounds | |
| ECSP10010347A (es) | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina | |
| DOP2011000329A (es) | Preparacion de solido | |
| MY161601A (en) | Films and compositions comprising the same | |
| ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene | |
| PH12015502122A1 (en) | Sovaprevir polymorphs and methods of manufacturing thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |